464 related articles for article (PubMed ID: 27890396)
21. Potential coverage of a multivalent M protein-based group A streptococcal vaccine.
Dale JB; Penfound TA; Tamboura B; Sow SO; Nataro JP; Tapia M; Kotloff KL
Vaccine; 2013 Mar; 31(12):1576-81. PubMed ID: 23375817
[TBL] [Abstract][Full Text] [Related]
22. Protective immunogenicity of group A streptococcal M-related proteins.
Dale JB; Niedermeyer SE; Agbaosi T; Hysmith ND; Penfound TA; Hohn CM; Pullen M; Bright MI; Murrell DS; Shenep LE; Courtney HS
Clin Vaccine Immunol; 2015 Mar; 22(3):344-50. PubMed ID: 25630406
[TBL] [Abstract][Full Text] [Related]
23. Safety and immunogenicity of a 30-valent M protein-based group a streptococcal vaccine in healthy adult volunteers: A randomized, controlled phase I study.
Pastural É; McNeil SA; MacKinnon-Cameron D; Ye L; Langley JM; Stewart R; Martin LH; Hurley GJ; Salehi S; Penfound TA; Halperin S; Dale JB
Vaccine; 2020 Feb; 38(6):1384-1392. PubMed ID: 31843270
[TBL] [Abstract][Full Text] [Related]
24. Lipid core peptide technology and group A streptococcal vaccine delivery.
Olive C; Batzloff MR; Toth I
Expert Rev Vaccines; 2004 Feb; 3(1):43-58. PubMed ID: 14761243
[TBL] [Abstract][Full Text] [Related]
25. Comparative in silico analysis of two vaccine candidates for group A streptococcus predicts that they both may have similar safety profiles.
Shaila MS; Nayak R; Prakash SS; Georgousakis M; Brandt E; McMillan DJ; Batzloff MR; Pruksakorn S; Good MF; Sriprakash KS
Vaccine; 2007 May; 25(18):3567-73. PubMed ID: 17293014
[TBL] [Abstract][Full Text] [Related]
26. Genetic diversity of Group A Streptococcus M protein: implications for typing and vaccine development.
Smeesters PR; Mardulyn P; Vergison A; Leplae R; Van Melderen L
Vaccine; 2008 Oct; 26(46):5835-42. PubMed ID: 18789365
[TBL] [Abstract][Full Text] [Related]
27. Multivalent group A streptococcal vaccine designed to optimize the immunogenicity of six tandem M protein fragments.
Dale JB
Vaccine; 1999 Jan; 17(2):193-200. PubMed ID: 9987154
[TBL] [Abstract][Full Text] [Related]
28. Toward the development of a synthetic group a streptococcal vaccine of high purity and broad protective coverage.
Horváth A; Olive C; Karpati L; Sun HK; Good M; Toth I
J Med Chem; 2004 Jul; 47(16):4100-4. PubMed ID: 15267249
[TBL] [Abstract][Full Text] [Related]
29. Molecular biology of Group A
Brahmadathan NK
Indian J Med Microbiol; 2017; 35(2):176-183. PubMed ID: 28681803
[TBL] [Abstract][Full Text] [Related]
30. Systematic Review and Meta-analysis of the Prevalence of Group A Streptococcal
Salie T; Engel K; Moloi A; Muhamed B; Dale JB; Engel ME
mSphere; 2020 Jul; 5(4):. PubMed ID: 32669471
[TBL] [Abstract][Full Text] [Related]
31. Updated model of group A Streptococcus M proteins based on a comprehensive worldwide study.
McMillan DJ; Drèze PA; Vu T; Bessen DE; Guglielmini J; Steer AC; Carapetis JR; Van Melderen L; Sriprakash KS; Smeesters PR
Clin Microbiol Infect; 2013 May; 19(5):E222-9. PubMed ID: 23464795
[TBL] [Abstract][Full Text] [Related]
32. Clinical and microbiological response of mice to intranasal inoculation with Lactococcus lactis expressing Group A Streptococcus antigens, to be used as an anti-streptococcal vaccine.
García PC; Paillavil BA; Scioscia N; Dale JB; Legarraga P; Salazar-Echegarai FJ; Bueno SM; Kalergis AM; Wozniak A
Microbiol Immunol; 2018 Nov; 62(11):711-719. PubMed ID: 30357922
[TBL] [Abstract][Full Text] [Related]
33. [Distribution of emm genotypes and antibiotic susceptibility of Streptococcus pyogenes strains: analogy with the vaccine in development].
Arslan U; Oryaşın E; Eskin Z; Türk Dağı H; Fındık D; Tuncer I; Bozdoğan B
Mikrobiyol Bul; 2013 Apr; 47(2):318-23. PubMed ID: 23621731
[TBL] [Abstract][Full Text] [Related]
34. Cross-reactive immunogenicity of group A streptococcal vaccines designed using a recurrent neural network to identify conserved M protein linear epitopes.
Spencer JA; Penfound T; Salehi S; Aranha MP; Wade LE; Agarwal R; Smith JC; Dale JB; Baudry J
Vaccine; 2021 Mar; 39(12):1773-1779. PubMed ID: 33642159
[TBL] [Abstract][Full Text] [Related]
35. Protection of mice from group A streptococcal infection by intranasal immunisation with a peptide vaccine that contains a conserved M protein B cell epitope and lacks a T cell autoepitope.
Olive C; Clair T; Yarwood P; Good MF
Vaccine; 2002 Jun; 20(21-22):2816-25. PubMed ID: 12034109
[TBL] [Abstract][Full Text] [Related]
36. Strategic development of the conserved region of the M protein and other candidates as vaccines to prevent infection with group A streptococci.
Good MF; Pandey M; Batzloff MR; Tyrrell GJ
Expert Rev Vaccines; 2015; 14(11):1459-70. PubMed ID: 26485214
[TBL] [Abstract][Full Text] [Related]
37. Development of conformational mimetics of conserved Streptococcus pyogenes minimal epitope as vaccine candidates.
Zhong W; Skwarczynski M; Toth I
Curr Drug Deliv; 2009 Oct; 6(5):520-7. PubMed ID: 19863488
[TBL] [Abstract][Full Text] [Related]
38. Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: phase 1 trial.
Kotloff KL; Corretti M; Palmer K; Campbell JD; Reddish MA; Hu MC; Wasserman SS; Dale JB
JAMA; 2004 Aug; 292(6):709-15. PubMed ID: 15304468
[TBL] [Abstract][Full Text] [Related]
39. Structure-activity relationship for the development of a self-adjuvanting mucosally active lipopeptide vaccine against Streptococcus pyogenes.
Zaman M; Abdel-Aal AB; Fujita Y; Ziora ZM; Batzloff MR; Good MF; Toth I
J Med Chem; 2012 Oct; 55(19):8515-23. PubMed ID: 22974133
[TBL] [Abstract][Full Text] [Related]
40. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.
Olive C; Sun HK; Ho MF; Dyer J; Horváth A; Toth I; Good MF
J Infect Dis; 2006 Aug; 194(3):316-24. PubMed ID: 16826479
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
